Use of metabolic syndrome severity to assess treatment with vitamin E and pioglitazone for non-alcoholic steatohepatitis.

ABSTRACT:

Background and aim

Non-alcoholic steatohepatitis (NASH), which can lead to liver failure, requires liver biopsies to follow and is difficult to treat. Our goal was to assess metabolic syndrome (MetS) severity as a predictor of treatment success and a marker of response.

Methods

We assessed data from the Pioglitazone, Vitamin E, or Placebo for NASH Study, in which individuals with biopsy-confirmed NASH were randomized to receive pioglitazone, vitamin E, or placebo for 96 weeks. We assessed associations of a sex-specific and race/ethnicity-specific MetS severity Z-score (MetS-Z) at baseline and 48 weeks with biopsy-determined endpoint of NASH resolution at 96 weeks.

Results

Baseline MetS-Z was inversely associated with odds of NASH resolution (odds ratio [OR] per 1 SD o

SUBMITTER: Gurka MJ 

PROVIDER: S-EPMC7719569 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature